- Cervical cancer: improvement of prevention necessary
- Ovarian cancer: new treatment options and improved treatment organization
- Endometrial cancer: a swallow of hope for relapsed patients
- Education is the basis
The COVID-19 pandemic has worsened the diagnosis and treatment of gynecological cancers in Poland. However, there are optimistic information: reimbursement of the first HPV vaccine in Poland. - In Europe, we have already registered new therapies for patients with ovarian and endometrial cancer. We are waiting for the possibility of their use in Poland - experts said during the conference "Gynecological tumors - time to act".
After a diagnosis of a gynecological cancer (including endometrial cancer, cervical cancer, ovarian cancer), Polish women live shorter lives than women in many other European countries. Although the incidence of cervical cancer is decreasing, it is still higher in Poland than in other countries, which indicates deficiencies in prevention and treatment. The incidence of ovarian and endometrial cancer is also increasing - shows the report"Challenges in oncological care in Poland - gynecological cancers and breast cancer" , prepared by the team experts and HTA Consulting.
-When it comes to prognosis and survival, the rates in Poland are improving for all gynecological cancers, but they are still 10-20 percentage points worse than in Western Europe - underlinedMagdalena Władysiuk , who edited the report.
The situation of patients with gynecological neoplasms was significantly worsened by the COVID-19 epidemic. -The fourth wave of COVID-19 is followed by the first or second wave of the cancer pandemic, which we will feel in the coming years. It is related to worse access to prophylaxis and delay in diagnosis. Particularly in the first months of the pandemic, a large part of prevention programs was suspended. Besides, the pandemic has obscured all problems; also many women decided that as long as they were not in pain, they could postpone a visit to the doctor- notedprof. Włodzimierz Sawicki , president of the Polish Society of Oncological Gynecology.
That is why women present themselves more often in the more advanced stages of cancer these days. This is especially true for ovarian cancer that doesn't show symptoms early. It is then more difficult to perform the optimal operation and it does not give satisfactory results. For the worsening of the effectsThe therapy may also have an impact on limiting the possibilities of surgical treatment, due to the transformation of some hospital wards into covid ones, as well as the shifting of some staff to work with COVID-19 patients.
Experts point out that better education, greater reporting for preventive examinations, and changes in diagnostics and treatment can, in many cases, save or significantly extend the life of women with gynecological neoplasms in Poland.
Cervical cancer: improvement of prevention necessary
Cervical cancer is a cancer in which it is possible to provide very effective prophylaxis in the form of vaccination against the HPV virus. Infections with this virus are responsible for 99 percent. cases of cervical cancer, and in 2006 the first vaccine against the HPV virus appeared. Many countries have implemented population-based immunization programs, which, combined with Pap and HPV screening testing, have resulted in a significant reduction in the incidence of cervical cancer.
-There are several countries, such as Switzerland and M alta, where this cancer has become casuistic: the incidence is less than 4 cases per 100,000. women. Australia was the first to announce a manifesto that in about 50 years it will bring cervical cancer down to the level of a very rare cancer. Already in 2007, a population-based immunization program for girls began there, and for many years boys have also been vaccinated against HPV- emphasizedprof. Andrzej Nowakowski , head of the Cervical Cancer Prevention Clinic at the Cancer Prevention Department of the National Oncology Institute Maria Skłodowskiej-Curie - National Research Institute in Warsaw.
In Poland, the incidence of cervical cancer is decreasing, although not as spectacularly as in other countries. -It is true that the cytological screening program did not achieve a spectacular success, as the attendance rate is 14-26%, we estimate, however, that systematic tests are performed by over 60%. women. Some do them privately, some within the National He alth Fund, but outside the preventive program, they are not registered. However, 30-40 percent. women do not perform cytology and it is especially them that should be reached by midwives and doctors- emphasized prof. Nowakowski. The number of preventive examinations dropped significantly during the COVID-19 epidemic. -In 2022, even 1/3 of women gave up on preventive examinations: some of the clinics were closed. Unfortunately, in 2-3 years' time we may see an increase in the incidence of cervical cancer- assessed prof. Nowakowski.
The good news is that from November 1, the first HPV vaccine was included in the reimbursement (you canbuy it with 50 percent. against payment, the vaccine is allowed over 9 years of age). -Being able to purchase the vaccine for 50% of the price is a big step forward in the prevention of cervical cancer. We are also waiting for the introduction of the population-based HPV vaccination program, we hope that it will happen from 2022, and the vaccination will be recommended, but free- said Prof. Nowakowski. The implementation of the program is assumed by the National Oncology Strategy (NSO). -We hope that boys will also be able to use vaccinations, in NSO it has been recorded since 2026- emphasizedKrystyna Wechmann , president of the Polish Patient Coalition Oncological.
Ovarian cancer: new treatment options and improved treatment organization
Ovarian cancer is one of the most difficult cancers to treat: every year in Poland approximately 3,700 women fall ill, and more than 2,600 die. -There is no screening test as for cervical cancer, so it is important to educate both women and GPs to refer patients to a gynecologist if they have prolonged gastrointestinal problems that may be the first, non-specific symptom. It is also important that women regularly visit the gynecologist and have transvaginal ultrasound examinations, although this also does not guarantee that ovarian cancer will be quickly detected- saidBarbara Górska , president of the association Blue Butterfly.
Although ovarian cancer mainly affects women in the perimenopausal age, it also affects 20-year-olds. Time is particularly important in its treatment, as ovarian cancer cells can spread rapidly throughout the abdominal cavity. -It is important that patients from the very beginning are taken under the care of appropriate doctors and specialized centers experienced in the management of women with ovarian cancer, and already during the first cytoreductive surgery, molecular tests are performed that will show the presence of mutations in BRCA1 genes , 2, which today determines further treatment. Unfortunately, many patients do not have these tests performed, although it should be a standard- emphasized the president Barbara Górska.
Experts want the Ovarian Cancer Unist network to be established in Poland; centers where women with ovarian cancer will have comprehensive care and treatment. -Currently, for example in Mazowieckie voivodship, ovarian cancer treatment is provided in 27 centers; there are those that perform 1-3 operations a year. Only two centers performed more than 20 procedures per year. It is similar in the whole of Poland- saidprof. Mariusz Bidziński , national consultant in the field ofoncological gynecology. If the center performs several operations a year, they are not performed optimally, which adversely affects the patients' further prognosis. They are sent to other centers, but a poorly performed first operation cannot be corrected.
The results of ovarian cancer treatment in Poland would also be improved by better access to modern drugs, such as PARP inhibitors. -These are drugs that extend the remission period, i.e. the time without disease symptoms. We are glad that in Poland it is possible to use one of the PARP inhibitors (olaparib) in both the first and second line of treatment, but the problem is that only women with mutations in the BRCA1, 2 genes can receive it. the other PAPR inhibitor (niraparib) also in patients without the mutation. The BRCA1, 2 mutation is a fundamental mutation in the DNA repair pathway, but there are also mutations in other genes that we cannot study today. Niraparib has proved to be effective in many clinical trials presented at world and European conventions. Introducing such treatment for patients without the mutation would increase the time until disease relapse. Ovarian cancer for many women can become a chronic disease, they can plan their family and professional life- saidprof. Włodzimierz Sawicki , president of the Polish Society of Oncological Gynecology. The form of therapy is also very convenient for patients. -These are oral medications, they are used at home. It is important for the psyche, the thought that "I am taking a pill for cancer" tames the disease- emphasized prof. Sawicki.
Endometrial cancer: a swallow of hope for relapsed patients
Cancer of the endometrium (endometrium) is the most common gynecological neoplasm, and the incidence in Poland is growing dynamically: between 1999 and 2022 there was a two-fold increase. -It is a cancer of highly civilized societies, you can say "cancer of prosperity". It often affects patients who have a good socioeconomic status, its occurrence is associated with the increasing life expectancy, but also with obesity, hypertension, and diabetes- explainedProf. Sawicki .
Endometrial cancer is usually diagnosed in the first stage of its advancement because it causes symptoms in the form of unusual uterine bleeding early. -Thanks to early detection, treatment results are good, 70-75 percent. of women has been living for more than 5 years since the diagnosis- emphasized prof. Sawicki. Like other cancers, however, it is not homogeneous: the prognosis for some subtypes may be unfavorable, so it is important to perform molecular tests and identify groups at risk of disease recurrence.
-HopeThere are new therapeutic options for patients with advanced cancer that recurs, as well as for some cytogenetic mutations. They are targeted drugs that target certain points of immune control. Immunotherapy is a "new chapter" in adjuvant therapy, the drug "exposes" the cancer cell to the immune system, so that it begins to fight cancer cells on its own. The drug is already registered in Europe, not reimbursed in Poland yet, but we hope that this will also change soon- emphasized prof. Sawicki.
Education is the basis
Despite the problems, before the COVID-19 epidemic in Poland, there was an improvement in the results of gynecological cancer treatment, which is why education is so important now, so that patients do not delay their preventive examinations and do not postpone visits to doctors if disturbing symptoms appear . -It is important to constantly raise women's he alth awareness, which will make them more allergic to their he alth- emphasizedMagdalena Władysiuk .
Women in Poland want to be treated at a similar level as in other EU countries, and thanks to more and more efficient patient organizations, they are increasingly aware of the importance of quick access to modern diagnostics, new treatment methods and good treatment. organization. -As patient organizations, we have great opportunities to provide information, and we also try to educate. Also, primary care physicians, nurses and midwives should pay more attention to educating patients, and be oncological vigilance. We are glad that education at school is being conducted more and more, from an early age, but a lot still needs to be improved- saidpresident Krystyna Wechmann .
According to Magdalena Władysiuk, the currently unfavorable difference in survival between women in Poland and some other EU countries can be viewed as an "indicator of hope", how much can still be improved. -There is a concept of Ovarian Cancer Units, we have good doctors who know how to treat, but they must be able to use modern drugs, it is also necessary to improve the organization of treatment, as well as improve financing, because today doctors resign from working in hospitals for Outpatient Specialist Care. There is a plan to improve the situation in gynecological oncology, a very ambitious path has been marked out. However, it is only when all the elements are put together that gynecological tumors will have a chance to become chronic diseases- saidProf. Włodzimierz Sawicki .